Attune Pharmaceuticals

Attune Pharmaceuticals (attunepharma.com): 3 changes recorded in its website history since August 2017.

The website did not answer the latest live check. Last tried 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

FundingBetween 22 April 2024 and 18 July 2024
Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation
FundingBetween 7 July 2019 and 26 November 2021
Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation
FundingBetween 7 August 2018 and 7 July 2019
Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation

First recorded website

Observed 10 August 2017

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel oral once-daily small-molecule therapeutics for the treatment of rare diseases.

archived page Link to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

Summary of the record · AI-written

Written by an AI model on 7 November 2026 from the dated observations above; this is not the date the changes happened; each point links to the changes it rests on.

Attune Pharmaceuticals highlights Series B financing

Attune Pharmaceuticals’ homepage features an announcement of $23M Series B financing to advance ATN-249 for the treatment of HAE across multiple observed periods.

Between August 2018 and July 2019, Attune Pharmaceuticals’ homepage announced “Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE”. [1]
Between July 2019 and November 2021, the company’s homepage showed the same $23M Series B financing announcement for ATN-249 for the treatment of HAE. [2]
Between April 2024 and July 2024, the homepage displayed the $23M Series B financing announcement to advance ATN-249 for the treatment of HAE. [3]
Reading: The presence of the $23M Series B announcement across these periods may suggest this financing is an important part of how Attune Pharmaceuticals presents itself. [1][2][3]

Cite this record

StartupHistory, “Attune Pharmaceuticals” company record, https://startuphistory.org/c/attunepharma.com

Machine-readable: /c/attunepharma.com.json. How changes are found: method.